Psyence Group Company Description
Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma.
It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
It also focuses on the research and development, cultivation, and production of psilocybin mushrooms and functional over-the-counter mushroom products.
The company offers its functional mushroom products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 2019 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
Contact Details
Address: 121 Richmond Street West Toronto, Ontario M5H 2K1 Canada | |
| Phone | 416-477-1708 |
| Website | psyence.com |
Stock Details
| Ticker Symbol | PSYGF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA74449Q1063 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jody Aufrichtig | Co-Founder and Executive Chairman |
| Adri Botha | Interim Chief Financial Officer |
| Taryn Vos | General Counsel |
| Tony Budden | Chief Strategy Officer |
| Mary-Elizabeth Gifford | Executive Vice President for Public Policy and Global Impact |